



April 18, 2026

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Symbol: LUPIN**

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Scrip Code: Equity - 500257**

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

**Dear Sir/Madam,**

We would like to inform you that the U.S. FDA has concluded an inspection at our manufacturing facility located in Somerset, New Jersey, U.S.A. The inspection was conducted from April 13, 2026 to April 17, 2026 and closed with the issuance of a Form-483 with three observations.

We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

Thanking you,

**For LUPIN LIMITED**

**AMIT KUMAR GUPTA**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**(ACS -15754)**

**LUPIN LIMITED**

**Registered Office:** 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. **Tel:** (91-22) 6640 2323.

**Corporate Identity Number:** L24100MH1983PLC029442

[info@lupin.com](mailto:info@lupin.com) | [www.lupin.com](http://www.lupin.com)